ArticleNano letters2026
HER2 Antibody-Nanogel Conjugates: A High-Capacity, Antibody-Sparing Alternative to Antibody-Drug Conjugates.
Article in Nano letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
HER2-targeted antibody-nanogel conjugates (ANCs) were developed with covalently encapsulated DM1 and benchmarked against the clinically optimized antibody-drug conjugate Kadcyla (T-DM1). In vitro, ANCs showed cytotoxicity comparable to that of T-DM1. In vivo, despite being at the proof-of-concept stage, HER2-DM1-ANC achieved equivalent antitumor efficacy in a BT-474 breast cancer xenograft model while requiring 4-fold less antibody. This reduced antibody usage may lessen the risk of tumor resistance, highlighting the unique advantage of the nanogel platform. The benefit stems from ANCs' higher drug-to-antibody ratio, achieved without chemical modification of the payload─a key bottleneck in ADC development. While T-DM1 represents a mature clinical product, these findings underscore ANCs as a high-capacity, modular nanoscale platform with significant potential for refinement and optimization in antibody-directed therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.